GTBP — GT Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $5.91m
- $1.96m
Annual cashflow statement for GT Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -28.3 | -58 | -20.9 | -7.6 | -13.2 |
| Depreciation | |||||
| Non-Cash Items | 21.6 | 35.2 | 7.66 | -3.08 | -0.517 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.596 | 7.25 | -1.99 | 1.82 | 0.775 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -7.26 | -15.6 | -15.2 | -8.85 | -12.9 |
| Other Investing Cash Flow Items | 0 | -23 | 12.1 | -2.01 | 12.9 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | -23 | 12.1 | -2.01 | 12.9 |
| Financing Cash Flow Items | — | — | -0.224 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 12.5 | 42.3 | -0.224 | 6.27 | 2.98 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.27 | 3.67 | -3.3 | -4.59 | 2.96 |